Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards

Stem Cells and Development

Volumn 24, Issue 18, 2015, Pages 2091-2100

  Munir, Hafsa ^a   McGettrick, Helen M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; CELL POPULATION; CROHN DISEASE; EX VIVO STUDY; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; LONG TERM CARE; MESENCHYMAL STEM CELL TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADVERSE EFFECTS; ANIMAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CYTOLOGY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STROMA CELL; MOUSE; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; CELL- AND TISSUE-BASED THERAPY; CROHN DISEASE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; T-LYMPHOCYTES;

EID: 84938841065     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0008     Document Type: Review

References (57)

1. Pal R, M Hanwate, M Jan and S Totey. (2009). Phenotypic and functional comparison of optimum culture conditions for upscaling of bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med 3:163-174.
2. Shi Y, G Hu, J Su, W Li, Q Chen, P Shou, C Xu, X Chen, Y Huang, et al. (2010). Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 20:510-518.
3. Luu NT, HM McGettrick, CD Buckley, P Newsome, GE Rainger, J Frampton and GB Nash. (2013). Crosstalk between mesenchymal stem cells and endothelial cells leads to down-regulation of cytokine-induced leukocyte recruitment. Stem Cells 31:2690-2702.
4. Le Blanc K and D Mougiakakos. (2012). Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12:383-396.
5. National Institutes of Health US. Available at: clincialtrials. gov. Accessed May 2015.
6. Trivanovic D, S Mojsilovic, V Ilic, J Krstic, A Jaukovic, I Okic-DorCevic, JF Santibanez, G Jovcic and D Bugarski. (2013). Immunomodulatory capacity of human mesenchymal stem cells isolated from adipose tissue, dental pulp, peripheral blood and umbilical cord Wharton's jelly. Cent Eur J Immunol 4:421-429.
7. Raffaghello L, G Bianchi, M Bertolotto, F Montecucco, A Busca, F Dallegri, L Ottonello and V Pistoia. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26:151-162.
8. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
9. François M, R Romieu-Mourez, M Li and J Galipeau. (2012). Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20:187-195.
10. Nemeth K, A Leelahavanichkul, PST Yuen, B Mayer, A Parmelee, K Doi, PG Robey, K Leelahavanichkul, BH Koller, et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42-49.
11. Cassatella MA, F Mosna, A Micheletti, V Lisi, N Tamassia, C Cont, F Calzetti, M Pelletier, G Pizzolo and M Krampera. (2011). Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29:1001-1011.
12. Benvenuto F, S Ferrari, E Gerdoni, F Gualandi, F Frassoni, V Pistoia, G Mancardi and A Uccelli. (2007). Human mesenchymal stem cells promote survival of T cells in a quiescent state. Stem Cells 25:1753-1760.
13. Li M, X Sun, X Kuang, Y Liao, H Li and D Luo. (2014). Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing NKG2D receptor expression and secretion of PGE2, IDO and TGF-b. Clin Exp Immunol 178:516-524.
14. Prevosto C, M Zancolli, P Canevali, MR Zocchi and A Poggi. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92:881-888.
15. Munir H, NT Luu, HM McGettrick and G Nash. (2013). Comparative ability of mesenchymal stem cells from different sources to regulate neutrophil recruitment by endothelial cells. In BSI Stromal Immunology Group 2nd Meeting, Cambridge, UK.
16. Prasanna SJ, D Gopalakrishnan, SR Shankar and AB Vasandan. (2010). Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One 5:e9016.
17. McGettrick HM, LM Butler, CD Buckley, GE Rainger and GB Nash. (2012). Tissue stroma as a regulator of leukocyte recruitment in inflammation. J Leukoc Biol 91:385-400.
18. Waterman RS, SL Tomchuck, SL Henkle and AM Betancourt. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 5:e10088.
19. Opitz CA, UM Litzenburger, C Lutz, TV Lanz, I Tritschler, A Köppel, E Tolosa, M Hoberg, J Anderl, et al. (2009). Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2, 3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 27:909-919.
20. Liotta F, R Angeli, L Cosmi, L Fil?, C Manuelli, F Frosali, B Mazzinghi, L Maggi, A Pasini, et al. (2008). Toll-like receptors 3 and 4 are expressed by human bone marrowderived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26:279-289.
21. Raicevic G, M Najar, B Stamatopoulos, C De Bruyn, N Meuleman, D Bron, M Toungouz and L Lagneaux. (2011). The source of human mesenchymal stromal cells influences their TLR profile as well as their functional properties. Cell Immunol 270:207-216.
22. Tyndall A and V Pistoia. (2009). Mesenchymal stem cells combat sepsis. Nat Med 15:18-20.
23. Gonzalez MA, E Gonzalez-Rey, L Rico, D Büscher and M Delgado. (2009). Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-989.
24. Chen QQ, L Yan, CZ Wang, WH Wang, H Shi, B Bin Su, QH Zeng, HT Du and J Wan. (2013). Mesenchymal stem cells alleviate TNBS-induced colitis by modulating inflammatory and autoimmune responses. World J Gastroenterol 19:4702-4717.
25. Duijvestein M, ME Wildenberg, MM Welling, S Hennink, I Molendijk, VL Van Zuylen, T Bosse, ACW Vos, ESM De Jonge-Muller, et al. (2011). Pretreatment with interferon-g enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29:1549-1558.
26. Garcia-Olmo D, M Garcia-Arranz, D Herreros, I Pascual, C Peiro and JA Rodriguez-Montes. (2005). A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48: 1416-1423.
27. De La Portilla F, F Alba, D Garc?a-Olmo, JM Herrer?as, FX Gonzalez and A Galindo. (2013). Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 28:313-323.
28. Duijvestein M, ACW Vos, H Roelofs, ME Wildenberg, BB Wendrich, HW Verspaget, EMC Kooy-Winkelaar, F Koning, JJ Zwaginga, et al. (2010). Autologous bone marrowderived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 15:1662-1669.
29. Zhou K, H Zhang, O Jin, X Feng, G Yao, Y Hou and L Sun. (2008). Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5:417-424.
30. Zhang Y, Y Xia, S Ni, Z Gu and H Liu. (2014). Transplantation of umbilical cord mesenchymal stem cells alleviates pneumonitis of MRL/lpr mice. J Thorac Dis 6: 109-117.
31. Ji S, Q Guo, Y Han, G Tan, Y Luo and F Zeng. (2012). Mesenchymal stem cell transplantation inhibits abnormal activation of Akt/GSK3 signaling pathway in T cells from systemic lupus erythematosus mice. Cell Physiol Biochem 29:705-712.
32. Schena F, C Gambini, A Gregorio, M Mosconi, D Reverberi, M Gattorno, S Casazza, A Uccelli, L Moretta, A Martini and E Traggiai. (2010). Interferon-g-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 62:2776-2786.
33. Youd M, C Blickarz, L Woodworth, T Touzjian, A Edling, J Tedstone, M Ruzek, R Tubo, J Kaplan and T Lodie. (2010). Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 161:176-186.
34. Sun L, K Akiyama, H Zhang, T Yamaza, Y Hou, S Zhao, T Xu, A Le and S Shi. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27: 1421-1432.
35. Liang J, H Zhang, B Hua, H Wang, L Lu, S Shi, Y Hou, X Zeng, GS Gilkeson and L Sun. (2010). Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 69:1423-1429.
36. Sun L, DWang, J Liang, H Zhang, X Feng, HWang, B Hua, B Liu, S Ye, et al. (2010). Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 62:2467-2475.
37. Liu Y, R Mu, S Wang, L Long, X Liu, R Li, J Sun, J Guo, X Zhang, et al. (2010). Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther 12:R210.
38. Bouffi C, C Bony, G Courties, C Jorgensen and D Noël. (2010). IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5:e14247.
39. Augello A, R Tasso, SM Negrini, R Cancedda and G Pennesi. (2007). Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 56:1175-1186.
40. Djouad F, V Fritz, F Apparailly, P Louis-Plence, C Bony, J Sany, C Jorgensen and D Noel. (2005). Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 52:1595-1603.
41. Sullivan C, JM Murphy, MD Griffin, RM Porter, CH Evans, C O'Flatharta, G Shaw and F Barry. (2012). Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Res Ther 14:R167.
42. Papadopoulou A, M Yiangou, E Athanasiou, N Zogas, P Kaloyannidis, I Batsis, A Fassas, A Anagnostopoulos and E Yannaki. (2012). Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Ann Rheum Dis 71:1733-1740.
43. Tormin A, O Li, JC Brune, S Walsh, B Schütz,MEhinger, N Ditzel, M Kassem and S Scheding. (2011). CD146 expression on primary nonhematopoietic bone marrow stem cells is correlated with in situ localization. Blood 117:5067-5077.
44. Eggenhofer E, F Luk, MH Dahlke and MJ Hoogduijn. (2014). The life and fate of mesenchymal stem cells. Front Immunol 5:1-6.
45. Sotiropoulou PA, SA Perez, M Salagianni, CN Baxevanis and M Papamichail. (2006). Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells 24:462-471.
46. Osiris therapeutics-Prochymal phase 3 Crohn's disease clinical trial. Available at: www. osiris. com/clinical-prochymal- crohns. php Accessed May, 2015.
47. Orbsen Mesenchymal stem cells. Available at: www . orbsentherapeutics. com/researchprojects. html Accessed May, 2015.
48. Von Bahr L, B Sundberg, L Lönnies, B Sander, H Karbach, H Hägglund, P Ljungman, B Gustafsson, H Karlsson, K Le Blanc and O Ringden. (2012). Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18:557-564.
49. Li XY, J Ding, ZH Zheng, ZB Wu and P Zhu. (2012). Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. Mol Med Rep 6:1183-1189.
50. Giuliani M, M Fleury, A Vernochet, F Ketroussi, D Clay, B Azzarone, JJ Lataillade and A Durrbach. (2011). Longlasting inhibitory effects of fetal liver mesenchymal stem cells on T-lymphocyte proliferation. PLoS One 6:e19988.
51. Karp JM and GS Leng Teo. (2009). Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4: 206-216.
52. Yang X, I Balakrishnan, B Torok-Storb and MM Pillai. (2012). Marrow stromal cell infusion rescues hematopoiesis in lethally irradiated mice despite rapid clearance after infusion. Adv Hematol 2012:ID 142530.
53. Eggenhofer E, V Benseler, A Kroemer, FC Popp, EK Geissler, HJ Schlitt, CC Baan, MH Dahlke and MJ Hoogduijn. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 3:297.
54. Kastrinaki M-C, P Sidiropoulos, S Roche, J Ringe, S Lehmann, H Kritikos, V-M Vlahava, B Delorme, GD Eliopoulos, et al. (2008). Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. Ann Rheum Dis 67:741-749.
55. Leijs MJC, GM van Buul, E Lubberts, PK Bos, JAN Verhaar, MJ Hoogduijn and GJVM van Osch. (2012). Effect of arthritic synovial fluids on the expression of immunomodulatory factors by mesenchymal stem cells: an explorative in vitro study. Front Immunol 3:231.
56. Kramann R, RK Schneider, DP DiRocco, F Machado, S Fleig, PA Bondzie, JM Henderson, BL Ebert and BD Humphreys. (2015). Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16:51-66.
57. Bi B, R Schmitt, M Israilova, H Nishio and LG Cantley. (2007). Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 18:2486-2496.